EZOSE SCIENCES AND SIGMA-TAU ADVANCE PROJECTS IN GLYCOMICS

Collaboration with Italian Pharmaceuticals Company
To Leverage Ezose’s Expertise in Glycan Analysis

PINE BROOK, NJ – April 10, 2012 – Ezose Sciences Inc. announced today a further agreement whereby Ezose’s glycomics capabilities will be applied to biologics research and development projects at SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

This new collaboration will build on R&D work conducted under prior agreements between Ezose and SIGMA-TAU. Financial terms and other details were not disclosed.

“We look forward to building on our past accomplishments and progressing our work with SIGMA-TAU scientists,” said Kiyoshi Nagata, Ph.D., Chairman and Chief Executive Officer of Ezose. “We are committed to enabling glycomics as a research tool of growing importance for our corporate partners.”

Marco Brughera, Corporate R&D Managing Director of SIGMA-TAU, said, “As a company committed to innovation, we rely not only on the contributions of SIGMA-TAU’s in-house scientific talent but also on the support of others who are pioneering their special fields. We welcome this opportunity to work with Ezose in bringing their unique glycomics capabilities to our research program.”

SIGMA-TAU, founded in Italy in 1957 and based in Pomezia (Rome, Italy), is a leading, all-Italian capital, international pharmaceutical group that invests in the research, development, and marketing of innovative and effective treatments to improve human well-being and quality of life, focusing in particular on immuno-oncology and biotechnology and on rare, neglected, and/or high social impact diseases.

About Glycomics
Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease.

Glycomics is a natural complement to genomics and proteomics, but it has traditionally been hindered by the lack of practical high-throughput and quantitative technologies. Ezose’s proprietary GlycanMap® platform addresses this need by combining, in an automated 96-well format, high-throughput glycan enrichment with specialized MALDI-TOF mass spectrometry and custom bioinformatics to both structurally identify and quantitate glycans present in complex biological samples. Such glycans can serve as novel biomarkers to aid in the development of drugs, vaccines, and diagnostic tests, including companion diagnostics. In addition, glycomics
holds potential for uncovering new therapeutic targets and mechanisms and for guiding the development and manufacture of glycosylated biologics and biosimilars.

**About Ezose**
Ezose (pronounced ā-zōse) Sciences Inc., based in Pine Brook, NJ, is dedicated to advancing glycomics to improve scientific understanding and healthcare. Ezose’s proprietary GlycanMap® technology platform brings a new dimension to biomarker discovery by enabling glycomics research on a scale comparable to that of genomics and proteomics. Ezose offers glycomics capabilities ranging from glycan analytics and biomarker discovery to diagnostic development and commercialization. The company tailors these capabilities to the needs of corporate partners under collaborative R&D and analytical-services agreements.

Established in 2009 as a US company, Ezose is an affiliate of the Diagnostics Division of Shionogi & Co., Ltd., Osaka, Japan.

For more information, visit [www.ezose.com](http://www.ezose.com).

**Forward Looking Statements**
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.

**Ezose business contact**
Scott A. Siegel, Ph.D., Vice President, Business Development
Main: 862-926-1950
Direct: 862-926-1952
Email: info@ezose.com

**Ezose media contact**
Richard Koenig at Biosyntax LLC
Office: 610-359-1626
Cell: 610-213-0725
Email: rick@biosyntaxllc.com
日本語要約

糖鎖解析プロジェクトに関する SIGMA-TAU 社との契約締結について


この新たなコラボレーションによって、従来からの契約に基づく開発作業を更に進めることになります。なお、経済的条件など詳細は公開しておりません。

Ezose の永田 清 chairman 兼 CEO は「これまでの成果を基に、SIGMA-TAU の研究者とともに研究開発を進められることを楽しみにしています。」とコメントしています。

また、SIGMA-TAU の Marco Brughera、 Corporate R&D Managing Director は、「SIGMA-TAU は、革新的な研究開発を進める会社として、社内の能力のみならず、新たな分野での先進的なパートナーからのサポートを活用することにしました。我々は、Ezose の画期的な糖鎖解析能力を用いて開発プログラムを進めることができることを歓迎しています。」とコメントしています。

SIGMA-TAU は 1957 年にイタリアで設立され、ボメチア（イタリア、ローマ）に拠点を置く、純イタリア資本の国際的な製薬グループです。人々の健康や QOL を改善する革新的で効果的な治療のための研究、開発、マーケティングを行っており、特に、腫瘍免疫やバイオテクノロジー分野あるいは、希少疾病、社会的に影響の大きい疾病に注力しています。